ProMIS Neurosciences (PMN) Competitors $0.96 -0.04 (-3.51%) (As of 11:20 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends PMN vs. CDTX, VTYX, RPTX, CRDL, PYXS, OTLK, IFRX, PLX, CNTX, and AVTXShould you be buying ProMIS Neurosciences stock or one of its competitors? The main competitors of ProMIS Neurosciences include Cidara Therapeutics (CDTX), Ventyx Biosciences (VTYX), Repare Therapeutics (RPTX), Cardiol Therapeutics (CRDL), Pyxis Oncology (PYXS), Outlook Therapeutics (OTLK), InflaRx (IFRX), Protalix BioTherapeutics (PLX), Context Therapeutics (CNTX), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical products" industry. ProMIS Neurosciences vs. Cidara Therapeutics Ventyx Biosciences Repare Therapeutics Cardiol Therapeutics Pyxis Oncology Outlook Therapeutics InflaRx Protalix BioTherapeutics Context Therapeutics Avalo Therapeutics ProMIS Neurosciences (NASDAQ:PMN) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, community ranking, analyst recommendations, profitability, earnings and media sentiment. Does the MarketBeat Community believe in PMN or CDTX? Cidara Therapeutics received 445 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 70.17% of users gave Cidara Therapeutics an outperform vote. CompanyUnderperformOutperformProMIS NeurosciencesOutperform Votes2100.00% Underperform VotesNo VotesCidara TherapeuticsOutperform Votes44770.17% Underperform Votes19029.83% Do insiders & institutionals believe in PMN or CDTX? 50.1% of ProMIS Neurosciences shares are held by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are held by institutional investors. 4.4% of ProMIS Neurosciences shares are held by company insiders. Comparatively, 7.6% of Cidara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media refer more to PMN or CDTX? In the previous week, Cidara Therapeutics had 4 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 6 mentions for Cidara Therapeutics and 2 mentions for ProMIS Neurosciences. Cidara Therapeutics' average media sentiment score of 0.53 beat ProMIS Neurosciences' score of 0.25 indicating that Cidara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProMIS Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cidara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, PMN or CDTX? ProMIS Neurosciences has higher earnings, but lower revenue than Cidara Therapeutics. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProMIS Neurosciences$10K3,145.43-$13.21M-$0.10-9.62Cidara Therapeutics$63.90M1.95-$22.93M-$25.52-0.69 Do analysts rate PMN or CDTX? Cidara Therapeutics has a consensus target price of $30.50, suggesting a potential upside of 72.61%. Given Cidara Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cidara Therapeutics is more favorable than ProMIS Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProMIS Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Is PMN or CDTX more profitable? ProMIS Neurosciences has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -289.05%. Cidara Therapeutics' return on equity of -69.64% beat ProMIS Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets ProMIS NeurosciencesN/A -636.20% -130.32% Cidara Therapeutics -289.05%-69.64%-33.73% Which has more risk and volatility, PMN or CDTX? ProMIS Neurosciences has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. SummaryCidara Therapeutics beats ProMIS Neurosciences on 13 of the 19 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get ProMIS Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMN vs. The Competition Export to ExcelMetricProMIS NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.45M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E Ratio-9.624.9791.2813.60Price / Sales3,145.43371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book4.3710.306.906.33Net Income-$13.21M$153.61M$118.83M$225.93M7 Day Performance-3.24%-1.73%-1.92%-0.96%1 Month Performance1.28%-7.26%-3.75%1.06%1 Year Performance-26.75%31.10%31.37%26.59% ProMIS Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMNProMIS Neurosciences1.1238 of 5 stars$0.96-3.5%N/A-30.8%$31.45M$10,000.00-9.626CDTXCidara Therapeutics4.1934 of 5 stars$17.67+16.9%$30.50+72.6%+0.9%$124.57M$63.90M-0.7090High Trading VolumeRPTXRepare Therapeutics2.672 of 5 stars$2.88+1.4%$10.00+247.2%-44.7%$122.43M$51.13M0.00180CRDLCardiol Therapeutics2.7497 of 5 stars$1.50-4.2%$8.75+485.3%+81.1%$121.99M$60,000.00-4.0020Analyst ForecastAnalyst RevisionNews CoveragePYXSPyxis Oncology1.0178 of 5 stars$2.05-46.3%$10.00+387.8%+165.3%$121.91MN/A-1.9660Analyst ForecastNews CoverageGap DownHigh Trading VolumeVTYXVentyx Biosciences2.4892 of 5 stars$1.71-0.9%$10.00+486.5%-27.1%$120.56MN/A-0.7373OTLKOutlook Therapeutics1.2029 of 5 stars$5.07-4.0%$48.20+850.7%-40.0%$119.96MN/A-0.4920PLXProtalix BioTherapeuticsN/A$1.61-4.7%N/A+22.0%$118.54M$65.49M-13.00200Analyst UpgradeIFRXInflaRx3.0863 of 5 stars$2.01-1.5%$8.00+298.0%+34.2%$118.35M$70,000.000.0060Gap UpCNTXContext Therapeutics2.0835 of 5 stars$1.51-7.4%$6.25+313.9%+81.1%$113.25MN/A-1.797Gap DownRANIRani Therapeutics3.1632 of 5 stars$2.02-1.5%$11.71+479.9%+2.5%$107.89M$2.72M0.00110Analyst Forecast Related Companies and Tools Related Companies Cidara Therapeutics Alternatives Ventyx Biosciences Alternatives Repare Therapeutics Alternatives Cardiol Therapeutics Alternatives Pyxis Oncology Alternatives Outlook Therapeutics Alternatives InflaRx Alternatives Protalix BioTherapeutics Alternatives Context Therapeutics Alternatives Avalo Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PMN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProMIS Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PMN Stock Alerts